Outcomes following general anaesthesia in children with hypertrophic cardiomyopathy

Gabrielle Norrish,1,2 Natalie Forshaw,3 Colleen Woo,3 Mary Claire Avanis,3 Ella Field,1 Elena Cervi,1 Akane Iguchi,3 Juan Pablo Kaski1,2

ABSTRACT

Background Children with hypertrophic cardiomyopathy (HCM) have historically been considered to be high-risk candidates for general anaesthesia (GA), but there is currently a paucity of evidence regarding the safety of anaesthesia and perioperative outcomes in this population.

Methods Clinical features and outcomes of all paediatric patients (<18 years) with HCM undergoing GA between 2000 and 2016 were reviewed.

Results 86 patients (median 12.4 years (IQR 6.5, 14.9)) underwent 164 separate GA procedures. Aetiology included non-syndromic disease (n=44, 56%), malformation syndromes (n=22, 26%), inborn error of metabolism (n=10, 12%) and neuromuscular disease (n=4, 5%). At the time of GA, mean maximal wall thickness (MWT) on echocardiography was 19 mm (SD±8 mm), 23 (14%) patients had severe left ventricular hypertrophy (MWT>30 mm) and 35 (21%) patients had a haemodynamically significant left ventricular outflow tract (LVOT) gradient (>50 mm Hg). The majority (n=143, 87%) had no perioperative complications. 20 (12%) patients had minor perioperative complications: bradycardia (n=4), hypotension (n=15) or transient ST segment changes (n=1). One (0.6% of GA procedures) patient experienced a cardiac arrest during anaesthetic induction with death occurring 3 days later. Clinical parameters (including age, MWT, LVOT gradient, systolic and diastolic dysfunction) were not associated with an increased risk of complications.

Conclusions This is the largest published series to date of paediatric patients with HCM undergoing GA, which demonstrates that, in an expert centre, patients can be anaesthetised with a relatively low periaesthetic mortality (0.6%) and prevalence of minor complications (12%). Future studies are required to systematically identify clinical features that may predict increased anaesthetic risk.

BACKGROUND

Hypertrophic cardiomyopathy (HCM) is the second most common cause of cardiomyopathy during childhood, with an estimated annual incidence of 0.24–0.47 per 100 000.1–3 The majority of disease is caused by mutations in the cardiac sarcomere protein genes,4 however aetiology is heterogeneous and also includes malformation syndromes, inborn errors of metabolism and neuromuscular diseases. Phenotypic expression is highly variable, but can include severe left ventricular hypertrophy (LVH), dynamic left ventricular outflow tract obstruction (LVOTO), impaired diastolic function and a predisposition to ventricular arrhythmias. The dynamic nature of LVOTO in HCM, caused by systolic anterior motion of the mitral valve, means that gradients can be exacerbated by changes in heart rate, heart rhythm, preload and/or afterload, with resulting haemodynamic instability. Although global systolic function is typically preserved, patients with HCM commonly have reduced LV compliance and diastolic dysfunction and are reliant on preload to maintain cardiac output. Finally, the hypertrophied left ventricle has an increased myocardial oxygen demand, resulting in a higher risk of coronary blood flow insufficiency and myocardial ischaemia. Given these characteristics, children with HCM have historically been viewed as high-risk general anaesthesia (GA) candidates. Perioperative outcomes of adult patients with HCM have been reported in the literature, although often with conflicting findings. However, there is currently a lack of evidence regarding the optimal perioperative management and safety of GA in the paediatric HCM population. The aim of this study was to determine the safety and outcomes of paediatric patients with HCM undergoing GA in a specialised centre.

PATIENTS AND METHODS

Patients

Clinical cardiac and anaesthetic data from children with HCM undergoing GA under the age of 18 years at Great Ormond Street Hospital between 2000 and 2016 were reviewed retrospectively. Patients were identified from anaesthetic records and a clinical
data collected from ambulatory ECG recordings. Levetiracetam, an oral anticonvulsant, was administered to patients with a history of seizures and/or neurodevelopmental delay (acquired/congenital) or short stature or high BMI. The incidence of complications was calculated as the number of patients experiencing an event divided by total patient-years. Cumulative incidence was estimated using Kaplan-Meier survival analysis. The association between continuous variables and complications was assessed using Wilcoxon rank-sum test. The association between categorical variables and complications was assessed using chi-square test or Fisher exact test. The association between continuous variables and complications was tested using multivariable logistic regression analysis with adjustment for potential confounders. All statistical analyses were performed using Stata (Stata Statistical Software: Release 14, College Station, TX: StataCorp). A p value of <0.05 was considered as statistically significant.

**Results**

**Demographics**

Eighty-six eligible patients with HCM under the age of 18 underwent 164 separate general anesthetics between 2000 and 2016. Seventy-eight (90%) patients had a history of seizures or neurodevelopmental delay (acquired/congenital). The median age at diagnosis was 12 years (range 0.5–18.4), and the median body weight was 30 kg (range 2–101). The median body surface area (BSA) was calculated to be 1.3 m² (range 0.6–2.9). The median body mass index (BMI) was 14.3 (range 4.5–32.4). The median BMI was 15.2 (range 5.0–32.1) in patients without a history of seizures or neurodevelopmental delay (acquired/congenital). The median BMI was 13.4 (range 4.5–32.1) in patients with a history of seizures or neurodevelopmental delay (acquired/congenital).

**Clinical characteristics**

The median age at diagnosis was 12.4 years (range 0–18.4). The median body weight was 30 kg (range 2–101). The median body surface area (BSA) was calculated to be 1.3 m² (range 0.6–2.9). The median body mass index (BMI) was 14.3 (range 4.5–32.4). The median BMI was 15.2 (range 5.0–32.1) in patients without a history of seizures or neurodevelopmental delay (acquired/congenital). The median BMI was 13.4 (range 4.5–32.1) in patients with a history of seizures or neurodevelopmental delay (acquired/congenital).

**Complications**

The incidence of complications was calculated as the number of patients experiencing an event divided by total patient-years. Cumulative incidence was estimated using Kaplan-Meier survival analysis. The association between continuous variables and complications was assessed using Wilcoxon rank-sum test. The association between categorical variables and complications was assessed using chi-square test or Fisher exact test. The association between continuous variables and complications was tested using multivariable logistic regression analysis with adjustment for potential confounders. All statistical analyses were performed using Stata (Stata Statistical Software: Release 14, College Station, TX: StataCorp). A p value of <0.05 was considered as statistically significant.

**Results**

**Demographics**

Eighty-six eligible patients with HCM under the age of 18 underwent 164 separate general anesthetics between 2000 and 2016. Seventy-eight (90%) patients had a history of seizures or neurodevelopmental delay (acquired/congenital). The median age at diagnosis was 12.4 years (range 0–18.4). The median body weight was 30 kg (range 2–101). The median body surface area (BSA) was calculated to be 1.3 m² (range 0.6–2.9). The median body mass index (BMI) was 14.3 (range 4.5–32.4). The median BMI was 15.2 (range 5.0–32.1) in patients without a history of seizures or neurodevelopmental delay (acquired/congenital). The median BMI was 13.4 (range 4.5–32.1) in patients with a history of seizures or neurodevelopmental delay (acquired/congenital).

**Clinical characteristics**

The median age at diagnosis was 12.4 years (range 0–18.4). The median body weight was 30 kg (range 2–101). The median body surface area (BSA) was calculated to be 1.3 m² (range 0.6–2.9). The median body mass index (BMI) was 14.3 (range 4.5–32.4). The median BMI was 15.2 (range 5.0–32.1) in patients without a history of seizures or neurodevelopmental delay (acquired/congenital). The median BMI was 13.4 (range 4.5–32.1) in patients with a history of seizures or neurodevelopmental delay (acquired/congenital).

**Complications**

The incidence of complications was calculated as the number of patients experiencing an event divided by total patient-years. Cumulative incidence was estimated using Kaplan-Meier survival analysis. The association between continuous variables and complications was assessed using Wilcoxon rank-sum test. The association between categorical variables and complications was assessed using chi-square test or Fisher exact test. The association between continuous variables and complications was tested using multivariable logistic regression analysis with adjustment for potential confounders. All statistical analyses were performed using Stata (Stata Statistical Software: Release 14, College Station, TX: StataCorp). A p value of <0.05 was considered as statistically significant.
Table 2  Indication for general anaesthetic

| Anaesthetic detail                                      | n (%) |
|---------------------------------------------------------|-------|
| Cardiac                                                 | 87 (53) |
| Implantation/threshold testing of ICD                   | 56    |
| Diagnostic cardiac catheterisation                      | 7     |
| Interventional cardiac catheterisation                  | 1     |
| EPS                                                     | 9     |
| Pacemaker implantation                                  | 8     |
| Loop recorder insertion                                 | 4     |
| Transoesophageal echocardiogram                         | 2     |
| General surgical                                        | 11 (7) |
| Gastrointestinal                                       | 7     |
| Biopsy/excision                                         | 4     |
| Radiology                                               | 26 (16) |
| Diagnostic                                              | 9     |
| Interventional                                          | 17    |
| Orthopaedic                                             | 12 (8) |
| Ears, nose and throat                                   | 8 (5) |
| Dental                                                  | 8 (5) |
| Plastics                                                | 2 (1) |
| Neurosurgery                                            | 2 (1) |
| Urology                                                 | 7 (4) |
| Respiratory                                             | 1 (<1) |

Data expressed as number (%). Total number of general anaesthesia (GA) procedures is 164.

Clinical phenotype at time of anaesthesia
Mean MLVWT at the time of anaesthesia was 19 mm (SD 8.3 mm, range 4–49 mm). The distribution of hypertrophy was asymmetric in 106 (68%) patients, concentric in 47 (30%) and biventricular in 3 (2%). Twenty-three (14%) patients had severe LVH. Of 47 (31%) patients with LVOTO at rest, 35 (21%) had a haemodynamically significant gradient (>50 mm Hg) and one had severe outflow tract obstruction (>90 mm Hg). Eighty-seven (53%) patients had echocardiographic evidence of impaired LV diastolic performance and 10 (6%) patients had impaired LV systolic function. Twenty-four (15%) patients had an implantable cardioverter defibrillator (ICD) in situ at the time of anaesthesia. One hundred and five (64%) patients had severe outflow tract obstruction (>90 mm Hg) and one after cardiac arrest requiring extracorporeal support (as described above). Length of stay ranged from 0 to 21 days (median 1 day); 104 (63%) procedures were on medical therapy for symptom control. Forty-six (28%) patients were on more than one medication (table 1).

Indication for general anaesthetic
One hundred and fifty (91%) general anaesthetics were for elective procedures. The indication for anaesthesia is shown in table 2.

Perioperative anaesthetic management
Details on perioperative anaesthetic management are summarised in table 3. The lead anaesthetic provider was a consultant cardiac anaesthetist in 75 (46%), consultant non-cardiac anaesthetist in 76 (46%) and a senior anaesthetic trainee doctor in 13 (8%). One hundred (61%) patients had an intravenous induction; phenylephrine was used empirically at induction in 8 (5%) patients with no subsequent recorded hypotension. In 153 (93%) patients, anaesthesia was maintained with volatile agents. All patients had invasive arterial blood pressure monitoring and 14 (9%) had central venous pressure monitoring.

Table 3  Perioperative management

| Anaesthetic detail                                      | n (%) |
|---------------------------------------------------------|-------|
| Lead anaesthetic provider                               |       |
| Consultant—cardiac                                      | 75 (46) |
| Consultant—non-cardiac                                  | 76 (46) |
| Senior trainee doctor                                   | 13 (8) |
| Anxiolytic premedication used                           | 34 (21) |
| Mode of induction                                       |       |
| Gaseous                                                 | 60 (37) |
| Sevoflurane                                             | 60    |
| Intravenous                                             | 100 (61) |
| Propofol and opioid                                     | 40    |
| Ketamine and opioid                                     | 5     |
| Propofol only                                           | 15    |
| Other                                                   | 7     |
| Mixed (intravenous+gas)                                 | 4 (2) |
| Airway management                                       |       |
| Endotracheal intubation                                 | 142 (87) |
| Laryngeal mask airway                                   | 19 (12) |
| Other                                                   | 3 (2) |
| Maintenance                                             |       |
| Volatile                                                | 153 (93) |
| Total intravenous anaesthesia                           | 9 (5) |
| Not specified                                           | 2 (1) |
| Vasopressor agent (n=17, 10%)                           |       |
| Phentolamine                                            | 14 (9) |
| Norepinephrine                                          | 3 (1) |

Data expressed as number (%).

Perioperative complications
Of a total of 164 anaesthetics in children with HCM, 143 (87%) had no perioperative complications. Twenty (12%) patients had minor perioperative complications: 15 patients had intraoperative hypotension requiring treatment; 4 had intraoperative bradyarrhythmia requiring treatment; and 1 had transient ST segment changes not requiring treatment. One (0.6%) patient had a major complication, with cardiac arrest occurring after induction of GA requiring extracorporeal-cardiopulmonary resuscitation and death occurring 3 days later. This patient had familial HCM with a severe phenotype: asymmetric hypertrophy (maximal wall thickness (MWT) 20 mm); LVOTO at rest (55 mm Hg) managed with medical therapy (atenolol and disopyramide) and short atrio-ventricular (AV) delay dual-chamber pacing; and evidence of LV diastolic impairment with left atrial dilatation. A primary prevention ICD had previously been implanted following syncopal events and the detection of NSVT on ambulatory ECG monitoring. No clinical parameters were associated with an increased risk of reaching the composite outcome of any postoperative complication (table 4).

Postoperative course
Postoperative recovery took place on a cardioiology ward for 91 (53%) patients, including 10 (6%) who had undergone non-cardiac procedures. Seventeen (10%) patients were managed postoperatively on intensive care, including two patients who had an unplanned admission: one following a failed extubation, and one after cardiac arrest requiring extracorporeal membrane oxygenator support (as described above). Length of stay ranged from 0 to 21 days (median 1 day); 104 (63%) procedures were...
completed as day case admissions and did not require an overnight stay.

DISCUSSION

To our knowledge, this is the largest study of perianesthetic outcomes in children with HCM to date. The results demonstrate that, in a heterogeneous cohort of patients with HCM having a GA at an experienced centre, the majority of patients (n=143, 87%) had no perioperative complications and two-thirds of procedures were performed as day cases requiring no overnight stay. Minor perioperative complications were seen in 12% of patients but there was 1 (0.6%) perioperative mortality in an adolescent with severe HCM.

Comparison with previous literature

To date, no large cohort studies describing the safety of GA in paediatric HCM have been published and most of the literature consists of single-case reports. The largest published paediatric series reported the outcome of 129 patients with different cardiomyopathies undergoing anaesthesia in a single centre, of whom 50 had HCM.11 No deaths were reported among the patients with HCM, but the study was limited by a lack of detailed clinical description of patients. The scarcity of paediatric data means that expected outcomes for these patients are often extrapolated from adult studies, the findings of which have been conflicting. Early reports described a high frequency of perianesthetic adverse events of up to 40% in adult patients with HCM.12 However, more recent studies describing larger populations of patients have reported a lower risk of cardiovascular adverse events, although the risk is nonetheless increased compared with controls.13 In the study by Dhillon and colleagues, 20% of patients with HCM reached a composite endpoint of death, MI, stroke or CCF; this was mostly driven by uncomplicated CCF and the absolute number of deaths, MI, or stroke was low and not significantly different from what was seen in an age-matched control group.14 The reported proportion of adult patients with HCM dying in the perioperative period in the literature ranges from 4% to 6.7%,15,14 which is higher than that seen in our cohort. This difference in mortality is unlikely to be explained by a milder disease phenotype. While the adult studies had a higher proportion of patients with LVOTO (53% vs 30.5%) and diastolic dysfunction (93% vs 55%), the absolute MWT and proportion of patients with a previous ventricular arrhythmia were not significantly different. The difference in mortality could be explained by the higher proportion of patients in the adult cohorts with additional comorbidities such as hypertension, diabetes and atrial fibrillation which are known to independently increase the risk of a GA.

Identifying patients at high risk of adverse events

Although the prevalence of adverse events is lower than historically reported, the ability to identify patients at higher risk would help guide clinical management. However, no data currently exist to guide perianesthetic risk stratification in paediatric HCM. In an adult cohort, the presence of LVOT obstruction at rest (gradient > 30 mm Hg), a high American Society of Anesthesiologists risk score15 and intraoperative hypotension were associated with a higher risk of having an adverse event.14 Our ability to systematically investigate individual risk factors for an adverse perioperative outcome in this study was limited by low numbers of adverse events in this cohort. No single parameter, including MLVWT, LVOTO and diastolic impairment, was found to be associated with a perianesthetic complication. However, it is likely that the combination of certain phenotypic features may confer a higher risk. Certainly, the single patient who experienced a major complication had severe disease with significant LVH, LVOTO, diastolic impairment and a history of ventricular arrhythmias. While larger studies are required to identify clinical features that may confer a higher anaesthetic risk, in clinical practice, it is essential that each individual patient is systematically assessed prior to a GA.

Importance of expert centres

Childhood HCM is a rare disease and compared with adult HCM populations, the disease in childhood is more heterogeneous in terms of aetiology, symptoms and outcomes.1,6-17 The cohort of childhood patients with HCM reported here is representative of other cohorts described in population-based or registry studies.1,2,18 It includes patients with phenotypically severe disease as defined by severe LVH, LVOTO, diastolic impairment and previous ventricular arrhythmias. The results are therefore likely to be generalisable to the wider paediatric HCM population. However, this cohort is derived from a single centre with medical, surgical and anaesthetic expertise in managing patients with this heterogeneous disease. To allow for individualised perioperative planning, a multidisciplinary team meeting (including the paediatric HCM specialists and anaesthetic consultants) is held in advance of any procedure requiring a general anaesthetic. The low prevalence of adverse outcomes may not be replicable in non-specialist centres. It is important to note that early reports from adult cohorts, which reported a higher prevalence of adverse events, were indeed derived from non-specialist centres. This includes the largest cohort of patients with HCM undergoing GA to date (n=227), which identified patients from the US National Hospital Discharge Survey,13 a fifth of whom underwent GA procedures in community-based hospitals which may lack the expertise to manage these patients. This study reported an increased risk of death (OR 1.61) or MI in adults with HCM compared with age-matched controls, a finding that has not been replicated in subsequent cohort studies from specialist centres. The low prevalence of adverse outcomes reported here highlights the importance of developing expertise at a specialist centre.

Limitations

This study is limited by problems inherent to retrospective studies, including missing or incomplete data. Additionally,
although this is the largest cohort of paediatric patients with HCM undergoing a GA reported in the literature, the interpretation of the prevalence of complications is limited by the absence of age-matched controls. Previous studies have reported 30-day mortality of 1.1/10 000 (95% CI 0.4 to 2.6) in a non-selective cohort of children undergoing GA at a tertiary paediatric hospital.\textsuperscript{19} In contrast, in the largest study to date, assessing outcomes following non-cardiac surgery in children with congenital heart disease (CHD), higher postoperative mortality 3.9%–8.2% rates were described in patients with moderate (defined as repaired CHD with residual haemodynamic abnormality) and severe (including patients with ventricular dysfunction requiring medication or uncorrected cyanotic heart disease) CHD compared with controls (1.7%–1.2%).\textsuperscript{20} This suggests that, although children with HCM have a higher incidence of major complications following anaesthesia compared with the general population, the risk may be lower than in children with other cardiac disease. This series did not include patients undergoing cardiac surgery requiring cardiopulmonary bypass (CPB) as the interpretation of the a priori defined complications (in particular disturbances in blood pressure, heart rate or arrhythmias) would not be possible once CPB was established. Future studies investigating the outcome of children with HCM undergoing GA for procedures requiring CPB would be useful.

CONCLUSION
This study reports the largest published series of patients with paediatric HCM undergoing GA and demonstrates a relatively low peri-anesthetic mortality (0.6%) and prevalence of minor complications (12%). The findings suggest that, in an expert centre, children with HCM can be anaesthetised with a low risk of adverse events. Future studies are required to systematically identify clinical features that may predict anaesthetic risk.

Contributors GN and NF conceptualised and designed the study, collected data, carried out the initial analyses, drafted the initial manuscript, and reviewed and revised the manuscript. CW and MCA conceptualised and designed the study, collected data, and reviewed and revised the manuscript. EF designed the study, collected data, and reviewed and revised the manuscript. CW and MCA conceptualised and designed the study, and critically reviewed the manuscript. EC and AI conceptualised and designed the study, collected data, and reviewed and revised the manuscript. EC and AI conceptualised and designed the study, and critically reviewed the manuscript. EF designed the study, collected data, and reviewed and revised the manuscript.

Funding This work was supported by the British Heart Foundation.

Competing interests None declared.

Patient consent Not required.

Ethics approval Great Ormond Street Hospital/University College London Institute of Child Health Research and Development Office.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

REFERENCES
1 Arola A, Jokinen E, Ruuskanen O, et al. Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. Am J Epidemiol 1997;146:385–93.
2 Nugent AW, Dauberney PE, Chondros P, et al. The epidemiology of childhood cardiomyopathy in Australia. N Engl J Med 2003;348:1639–46.
3 Colan SD, Lipschultz SE, Lowe AM, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation 2007;115:733–81.
4 Kaski JP, Syrjä P, Esteban MT, et al. Prevalence of sarcomere protein gene mutations in preadolescent children with hypertrophic cardiomyopathy. Circ Cardiovasc Genet 2009;2:436–41.
5 Elliott P, Andressson B, Arbusinì E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008;29:270–6.
6 Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2733–79.
7 Anon. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016;17:412.
8 Nagae ML, Smisek DA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2016;17:1321–60.
9 Wigle ED, Sasson Z, Henderson MA, et al. Hypertrophic cardiomyopathy: the importance of the site and the extent of hypertrophy. A review. Prog Cardiovasc Dis 1985;28:1–83.
10 Du Bois D, Du Bois EF. A formula to estimate the approximate area surface if height and weight be known. 1916. Nutrition 1989;5:303–11. discussion 312-303.
11 Lynch J, Pehora C, Holby H, et al. Cardiac arrest upon induction of anaesthesia in children with cardiomyopathy: an analysis of incidence and risk factors. Paediatr Anaesth 2011;21:951–7.
12 Haering JM, Comunale ME, Parker RA, et al. Cardiac risk of noncardiac surgery in patients with asymmetric septal hypertrophy. Anesthesiology 1996;85:254–9.
13 Hoefje H, Zahid M, Sonel A, et al. Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clin Cardiol 2006;29:65–8.
14 Dhillon A, Kharina A, Randhawa MS, et al. Perioperative outcomes of patients with hypertrophic cardiomyopathy undergoing non-cardiac surgery. Heart 2016;102:1627–32.
15 Dries RO, Lamont A, Eckenhoff JE. The role of anesthesia in surgical mortality. JAMA 1997;1178:261–6.
16 Nugent AW, Dauberney PE, Chondros P, et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005;112:1332–8.
17 Lipschultz SE, Orav EJ, Wilkinson JD, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet 2013;382:1889–97.
18 Lipschultz SE, Sleeper LA, Towbin JA, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med 2003;348:1647–55.
19 de Bruin L, Pasma W, van der Werff DB, et al. Perioperative hospital mortality at a tertiary paediatric institution. Br J Anaesth 2015;115:608–15.
20 Ng SM, Jin X, Yates R, et al. Outcome of noncardiac surgery in children with congenital heart disease performed outside a cardiac center. J Pediatr Surg 2016;51:252–6.